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ABSTRACT: The two-peptide lantibiotic haloduracin is
composed of two post-translationally modiﬁed polycyclic
peptides that synergistically act on Gram-positive bacteria.
We show here that Halα inhibits the transglycosylation
reaction catalyzed by PBP1b by binding in a 2:1 stoichiom-
etry to its substrate lipid II. Halβ and the mutant Halα-
E22Q were not able to inhibit this step in peptidoglycan
biosynthesis, but Halα with its leader peptide still attached
was a potent inhibitor. Combined with previous ﬁndings,
thedatasupportamodelinwhicha1:2:2lipidII:Halα:Halβ
complex inhibits cell wall biosynthesis and mediates pore
formation, resulting in loss of membrane potential and
potassium eﬄux.
I
nhibition of peptidoglycan biosynthesis is a common mode of
action of many natural product antibiotics. Among the various
ways of disrupting cell wall biosynthesis, sequestration of lipid II
(Figure 1A) is particularly powerful. Lipid II is the substrate for
the polymerases that generate the oligosaccharide chains of
peptidoglycan. Bacterial resistance to compounds that bind to
lipid II, such as nisin,
1 vancomycin,
2 and ramoplanin,
36 has
been slowtodevelop, possibly becauseincomparisonwithother
resistance mechanisms such as eﬄux pumps and enzyme muta-
tions, it is more challenging to change the structure of an
advanced intermediate that is biosynthesized in 10 steps.
7,8
Severalstructurallydiversemembersofthelantibioticshave
beenreportedto bindtolipidII.
1,913Lantibioticsare riboso-
mally synthesized and post-translationally modiﬁed peptides
characterized by thioether cross-links.
14 Two-peptide lanti-
bioticsconsistoftwocompoundsthatfunction synergistically
to kill a range of Gram-positive bacteria.
15 In a recently
proposed model for their synergistic activity, the α-peptide
bindstolipidIIinstoichiometricfashion,generatingabinding
site for the β-peptide.
12,16 A 1:1:1 trimeric complex is then
believed to form pores in the cell membrane, which results in
the eﬄux of potassium and disruption of the membrane
potential.
12 In this work, we evaluated this model with the
two-peptide lantibiotic haloduracin and carried out structure
activity studies with haloduracin analogues. We show that
the stoichiometry of binding lipid II by the α-peptide of
haloduracin is 1:2 (lipid II:Halα).
The two peptides that make up haloduracin are shown in
Figure 1B.
17,18 Halα contains several overlapping rings, includ-
ing the B ring (residues 1823) that is present in a variety of
lantibiotics (including mersacidin
10 and lacticin 3147
19)a n d
has been proposed to be important for lipid II binding.
20,21
Halβ has a more elongated structure and does not contain any
overlapping rings (Figure 1B). To evaluate binding to lipid II,
we used a previously reported in vitro assay that monitors the
catalytic activity of PBP1b from Escherichia coli.
22 PBP1b uses
lipid II as a substrate for glycan polymerization. Halα inhibited
PBP1b-catalyzed peptidoglycan formation using 4 μMh e p t a -
prenyl lipid II 1 (Figure 1A) with a half-maximal inhibitory
concentration (IC50)o f9 . 6( 0.4 μM (Figure 2). In contrast,
Halβ did not inhibit lipid II polymerization at concentrations
up to 100 μM. We also tested a series of other post-transla-
tionally modiﬁed peptides as potential inhibitors of the polym-
erization process. The lantibiotics epilancin 15X,
23 lactocin
S,
24,25 and cinnamycin
26,27 did not demonstrate any inhibitory
activity at concentrations up to 200 μM. Similarly, the S-linked
glycopeptide sublancin
28 did not inhibit lipid II polymerization
attheselevels.Wethereforeconcentratedourfurthereﬀortson
haloduracin.
A Halα mutant in which Cys23 was mutated to Ala,
29,30
thereby disrupting the B-ring structure, still inhibited lipid II
polymerization, albeit with a 5-fold increase in the IC50 value
(50.7 ( 1.7 μM) relative to wild-type (wt) Halα (Figure S1 in
the Supporting Information). Mutation of the highly conserved
Glu22 within the B ring to Gln abolished inhibition at concen-
trations up to 100 μM. However, a C-ring Cys27 f Ala mutant
did inhibit polymerization, but in a less potent manner than wt
Halα (IC50 = 29.5 ( 3.5 μM; Figure S1). The B- and C-ring
mutantswerepreviouslyevaluatedfortheirantimicrobialactivity
against Lactococcus lactis HP.
29,30 The combination of wt Halα
andHalβresultedinaminimuminhibitoryconcentration(MIC)
of 0.039 μM, whereas the use of wt Halβ with Halα-C23A or
Halα-C27A yielded MIC values of 0.39 and 1.56 μM, respec-
tively. It is not possible to compare directly the eﬀects of these
mutations on the antimicrobial activity and in vitro inhibition of
lipid II polymerization because of diﬀerent components that are
present in each assay, including the membrane of whole cells in
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the antimicrobial assay. Nevertheless, the relative eﬀects can be
compared for each assay type. The larger deleterious eﬀect on
antimicrobial activity of the C27A mutation compared to the
C23AmutationdespiteitshigheraﬃnityforlipidIIsuggeststhat
disruptionoftheCringhasanadditionaldeleteriouseﬀectonthe
interaction with Halβ compared with disruption of the B ring.
Conversely, the Halα-E22Q MIC of 1.56 μM when combined
with wt-Halβ
30 was not expected given that the peptide did not
inhibitinvitropolymerization.Inthecontextofthemembraneof
whole cells and the presence of Halβ, the compound may regain
some of its binding activity. Binding is still very weak, however,
because the MIC of the combination treatment is only 4-fold
lower than that of Halβ by itself (6.25 μM).
The kinetics of the inhibition of the polymerization reaction
catalyzedbyPBP1bwereexaminednextwithwtHalα.Asshown
in Figure 3, the dependence of the reaction rate on the lipid II
concentration exhibits MichaelisMenten-like kinetics. In the
presence of 6 μM Halα, the reaction was fully inhibited until
the lipid II concentration exceeded 3 μM. Similarly, at a Halα
concentration of 8 μM, the reaction was completely inhibited
until the lipid II concentration exceeded 4 μM. This type of
behavior is similar to the inhibition of this process by
ramoplanin
31 and indicates that Halα forms a tight complex
with lipid II with a 2:1 stoichiometry (Halα:lipid II).
32 This
stoichiometry is reminiscent of the 2:1 ratio of nisin to lipid II in
pores formed in bacterial membranes.
33 The data do not allow a
precise determination of a KD for Halα binding to lipid II,
34 but
the inhibition curves in Figure 3 imply a nanomolar binding
constant. Because previous work has demonstrated that like
other two-peptide lantibiotics,
16 Halα and Halβ act in 1:1
stoichiometry,
30 the data further suggest that haloduracin in-
hibits peptidoglycan formation and causes pore formation by
forming a lipid II:Halα:Halβ complex with 1:2:2 stoichiometry.
The Halα mutants used in this work were made using a
previously described in vitro reconstituted biosynthesis.
17,29 In
this process, the lanthionine synthetase HalM1 carries out a
seriesofpost-translationalmodiﬁcationsontheHalA1precursor
peptide that result in the thioether cross-links shown in
Figure 1B. The precursor peptide has an additional N-terminal
extension of 41 amino acids called the leader peptide that is
important for recognition by HalM1. In addition, the leader
peptides of lantibiotic precursor peptides are generally believed
to keep their products inactive while they are synthesized in the
cytoplasm.
3539 For haloduracin, the bifunctional protease/
transporter HalT is believed to remove the leader peptide. HalT
has not been investigated to date, but in a related system for the
lantibiotic lacticin 481, the dedicated protease domain of the
Figure 1. (A) Structures of lipid II and an analogue 1 used in this study
withashortenedprenylchain.(B)StructuresofHalαandHalβ.Shaded
circlesindicateresiduesmutatedinthisstudy.Abu,2-aminobutyricacid;
Dhb, dehydrobutyrine.
Figure 2. Inhibition of PBP1b-catalyzed formation of peptidoglycan
(PG) by Halα and Halβ. The lipid II concentration was 4 μM.
Figure 3. Kinetics of lipid II polymerization by PBP1b and inhibition
of this process by Halα.17546 dx.doi.org/10.1021/ja206281k |J. Am. Chem. Soc. 2011, 133, 17544–17547
Journal of the American Chemical Society COMMUNICATION
transporter LctT removes the leader peptide of modiﬁed LctA
precursor peptide and secretes the ﬁnal product.
37,40 Given the
common belief that lantibiotics with their leader peptides still
attached are inactive, we were surprised to ﬁnd that Halα
containing its leader peptide (leader-Halα) appeared to have
antimicrobial activity against L. lactis HP when combined with
Halβ(Figure4A). The activity is low relative to Halαwithout its
leaderpeptideattached,andantimicrobialactivityofleader-Halα
was seen only in the presence of Halβ. We speculated that the
indicator strain may secrete a protease that removes all or part of
the leader peptide from a small subset of Halα molecules,
resulting in the observed activity. Alternatively, Halα with its
leader peptide attached may still engage with lipid II. To test the
latterexplanation,thepolymerizationassaywasconductedinthe
presence of leader-Halα. Indeed, this peptide proved to be a
potent inhibitor of lipid II polymerization with an IC50 of 7.1 (
0.2 μM (with 4 μM lipid II; Figure 4B), similar to the activity of
wt-Halα. The weaker antimicrobial activity of leader-Halα with
wt Halβ relative to Halα combined with Halβ (Figure 4A) is
likelyaconsequenceofthelessoptimalsynergy betweenthetwo
peptides when the leader peptide is still attached to Halα.
Furthermore, the leader peptide of Halα is highly negatively
charged (four Glu, three Asp, one Arg, one Lys)
17,18 with a
stretch of four negatively charged residues near the junction
between the leader peptide and the core peptide. These negative
charges are likely to signiﬁcantly weaken the binding of leader-
HalαtolipidIIinthecontextofanegativelychargedmembrane,
explaining why the antimicrobial activity in Figure 4A is weaker
than anticipated on the basis of the strong inhibition of the
polymerization process by leader-Halα.
Insummary,thisstudyhasshownthatHalαinhibitsPBP1bby
binding to its substrate lipid II in 2:1 stoichiometry. Glu22 is
essentialforthis interaction, andthe Band Crings are important
but not critical. Attachment of the leader peptide does not
prevent Halα from binding to lipid II, but because the leader is
removed during secretion, lipid II does not encounter leader-
Halα in the context of the producer strain. In combination with
previous studies, the results presented here suggest that halodur-
acin’s antimicrobial activity is achieved in 1:2:2 lipid II:Halα:
Halβ stoichiometry.
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